Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0

作者：

Ritchlin, Christopher T. ^{[1
]}

Mease, Philip J. ^{[2
,3
]}

Boehncke, Wolf-Henning ^{[4
]}

Tesser, John ^{[5
]}

Chakravarty, Soumya D. ^{[6
,7
]}

Rampakakis, Emmanouil ^{[8
,9
]}

Shawi, May ^{[10
]}

Merola, Joseph F. ^{[11
]}

McInnes, Iain B. ^{[12
]}

Deodhar, Atul ^{[13
]}

机构：

[1] Univ Rochester, Med Ctr, Rochester, NY USA

[2] Swedish Med Ctr, Providence St Joseph Hlth, Seattle, WA USA

[3] Univ Washington, Seattle, WA USA

[4] Univ Geneva, Univ Hosp Geneva, Div Dermatol, Geneva, Switzerland

[5] Arizona Arthrit & Rheumatol Associates, Phoenix, AZ USA

[6] Janssen Sci Affairs LLC, Horsham, PA USA

[7] Drexel Univ, Coll Med, Philadelphia, PA USA

[8] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[9] JSS Med Res Inc, Montreal, PQ, Canada

[10] Johnson & Johnson, Janssen Pharmaceut Co, Immunol Global Med Affairs, Horsham, PA USA

[11] Harvard Med Sch, Brigham & Womens Hosp, Div Rheumatol & Immunol, Boston, MA USA

[12] Univ Glasgow, Coll Med Vet & Life Sci, Glasgow, Scotland

[13] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portland, OR USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

42148

引用

页码：AB225 / AB225

页数：1

共 50 条

[1] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Ritchlin, Christopher
Mease, Philip J.
Boehncke, Wolf-Henning
Tesser, John
Chakravarty, Soumya
Rampakakis, Emmanouil
Shawi, May
Schiopu, Elena
Merola, Joseph
McInnes, Iain B.
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4178 - 4182
[2] STRINGENT DISEASE ACTIVITY CONTROL AT 2 YEARS ACROSS PSORIATIC ARTHRITIS DOMAINS IRRESPECTIVE OF BASELINE CHARACTERISTICS IN PATIENTS TREATED WITH GUSELKUMAB: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLEBLIND, PLACEBO-CONTROLLED STUDY
Ritchlin, C. T.
Mease, P. J.
Boehncke, W. H.
Tesser, J.
Chakravarty, S. D.
Rampakakis, E.
Shawi, M.
Schiopu, E.
Merola, J. F.
Mcinnes, I.
Deodhar, A.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1779 - 1780
[3] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated With Guselkumab: Posthoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher
Mease, Philip
Boehncke, Wolf-Henning
Tesser, John
Allard-Chamard, Hugues
Chakravarty, Soumya
Rampakakis, Emmanouil
Shawi, May
Schiopu, Elena
Merola, Joseph
McInnes, Iain
Deodhar, Atul
JOURNAL OF RHEUMATOLOGY, 2023, 50 (07) : 29 - 30
[4] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Ritchlin, Christopher
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Adelakun, Oyediran
Rampakakis, Emmanouil
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
[5] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
Ritchlin, Christopher T.
Lubrano, Ennio
Chimenti, Maria Sole
Leibowitz, Evan
Sharaf, Mohamed
Rampakakis, Emmanouil
Chakravarty, Soumya
Nantel, Francois
Lavie, Frederic
Deodhar, Atul
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
[6] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
Coates, Laura C.
Gossec, Laure
Zimmermann, Miriam
Shawi, May
Rampakakis, Emmanouil
Shiff, Natalie J.
Kollmeier, Alexa P.
Xu, Xie L.
Nash, Peter
Mease, Philip J.
Helliwell, Philip S.
RMD OPEN, 2024, 10 (01):
[7] Guselkumab Efficacy in Active Psoriatic Arthritis Patients with or Without Hyperuricemia: Post-hoc Analysis of Two Phase 3, Randomized, Double-blind, Placebo-Controlled Studies
Felten, Renaud
Widawski, Laura
Spielman, Lionel
Gottenberg, Jacques-Eric
Duret, Pierre-Marie
Rampakakis, Emmanouil
Sharaf, Mohamed
Constantin, Caren
Campana, Vincenza
Messer, Laurent
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4429 - 4432
[8] SERUM EXTRACELLULAR MATRIX BIOMARKERS IDENTIFY RESPONSE TO GUSELKUMAB IN PSORIATIC ARTHRITIS: POST-HOC ANALYSIS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY THROUGH 2 YEARS
Nielsen, S. Holm
Bay-Jensen, A. C.
Frederiksen, P.
Karsdal, M.
Shawi, M.
Chakravarty, S. D.
Kollmeier, A.
Chen, W.
Gao, S.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 342 - 343
[9] Serum Extracellular Matrix Biomarkers Identify Response to Guselkumab in Psoriatic Arthritis; Post-hoc Analysis from a Phase 3, Randomized, Double-blind, Placebo-controlled Study Through 2 Years
Nielsen, Signe Holm
Bay-Jensen, Anne-Christine
Frederiksen, Peder
Karsdal, Morten
Shawi, May
Chakravarty, Soumya
Kollmeier, Alexa
Chen, Warner
Gao, Sheng
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4219 - 4220
[10] Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
Kavanaugh, Arthur
Lam, Gordon
Tam, Lin-Shan
Shiff, Natalie
Lee, Youngja
Perdomo, Ana-Maria Bravo
Shawi, May
Hsia, Elizabeth
Rampakakis, Emmanouil
Gutierrez, Carlos Enrique Toro
ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4170 - 4172

← 1 2 3 4 5 →